Our meta-analysis compared the expression of FOXC2 in stage T1-T2 and stage T3-T4 tumors, and we reduced selection bias by restricting our analysis to multivariate cohort studies that detected FOXC2 expression via immunohistochemical staining and based the T-stage definition on tumor size, which does not predict morbidity but is a definitive indicator of tumor growth. Here, FOXC2 is linked to neoplasm.